Market Cap : 445.39 M | Enterprise Value : 198.84 M | PE Ratio : At Loss | PB Ratio : 1.81 |
---|
NAS:ATRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ATRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2022-08-18), Atara Biotherapeutics's share price is $4.72. Atara Biotherapeutics's Tangible Book per Share of Jun. 2022 for the quarter that ended in Jun. 2022 was $2.73. Hence, Atara Biotherapeutics's Price to Tangible Book Ratio of today is 1.73.
The historical rank and industry rank for Atara Biotherapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 10 years, Atara Biotherapeutics's highest Price to Tangible Book Ratio was 8.54. The lowest was 1.62. And the median was 3.13.
ATRA's Price-to-Tangible-Book is ranked better thanA closely related ratio is called PB Ratio. As of today, Atara Biotherapeutics's share price is $4.72. Atara Biotherapeutics's Book Value per Sharefor the quarter that ended in Jun. 2022 was $2.73. Hence, Atara Biotherapeutics's P/B Ratio of today is 1.73.
The historical data trend for Atara Biotherapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atara Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Price-to-Tangible-Book falls into.
Atara Biotherapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Jun. 2022 ) |
= | 4.72 | / | 2.729 | |
= | 1.73 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Atara Biotherapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Yarema Kristin | officer: Chief Commercial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Murugan Amar | officer: SVP, GC & Secretary | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Dupont Jakob | officer: EVP, Head of R&D | C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 |
Touchon Pascal | director, officer: President and CEO | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Koppikar Utpal | officer: Chief Financial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Mallik Ameet | director | C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102 |
Renaud Ronald C Jr | director | C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109 |
Seidenberg Beth C | director | |
Heiden William K | director | C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 |
Dobmeier Eric | director | C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021 |
Roncarolo Maria Grazia | director | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Gallagher Carol Giltner | director | C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 |
Fust Matthew K | director | C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 |
Baynes Roy D. | director | C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 |
Berger Dietmar | officer: Global Head of R&D | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Other Sources
By tipranks.com 2022-04-04
By tipranks.com 2022-03-22
By Zacks 2021-01-26
By tipranks.com 2022-02-28
By tipranks.com 2022-03-18
By Fool 2022-02-18
By Zacks 2021-11-04